The prognostic value of expression of HIF1α, EGFR and VEGF-A, in localized prostate cancer for intermediate- and high-risk patients treated with radiation therapy with or without androgen deprivation therapy

Radiation Oncology

Volumn 7, Issue 1, 2012, Pages

  Weber, Damien C ^a   Tille, Jean Christophe ^a   Combescure, Christophe ^a   Egger, Jean François ^a   Laouiti, Mahomet ^a   Hammad, Karim ^a   Granger, Perrine ^b   Rubbia Brandt, Laura ^a   Miralbell, Raymond ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b Unilabs   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CARBONATE DEHYDRATASE IX; EPIDERMAL GROWTH FACTOR RECEPTOR; HYPOXIA INDUCIBLE FACTOR 1ALPHA; VASCULOTROPIN A;

ADULT; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; CANCER GROWTH; CANCER LOCALIZATION; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CONTROLLED STUDY; FOLLOW UP; GLEASON SCORE; HIGH RISK PATIENT; HUMAN; IMMUNOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; PROTEIN EXPRESSION; RADIATION DOSE; TREATMENT DURATION;

AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; DISEASE-FREE SURVIVAL; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASM GRADING; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSTATIC NEOPLASMS; RADIOTHERAPY; RECEPTOR, EPIDERMAL GROWTH FACTOR; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84862229124     PISSN: None     EISSN: 1748717X     Source Type: Journal    
DOI: 10.1186/1748-717X-7-66     Document Type: Article

References (27)

1. Li R, Younes M, Wheeler TM, Scardino P, Ohori M, Frolov A, et al. Expression of vascular endothelial growth factor receptor-3 (VEGFR-3) in human prostate. Prostate 2004 Feb 1, 58(2):193-199.
2. Zhong H, Semenza GL, Simons JW, De Marzo AM. Up-regulation of hypoxia-inducible factor 1alpha is an early event in prostate carcinogenesis. Cancer Detect Prev 2004, 28(2):88-93. 10.1016/j.cdp.2003.12.009, 15068831.
3. Boddy JL, Fox SB, Han C, Campo L, Turley H, Kanga S, et al. The androgen receptor is significantly associated with vascular endothelial growth factor and hypoxia sensing via hypoxia-inducible factors HIF-1a, HIF-2a, and the prolyl hydroxylases in human prostate cancer. Clin Cancer Res 2005 Nov 1, 11(21):7658-7663.
4. Mori R, Dorff TB, Xiong S, Tarabolous CJ, Ye W, Groshen S, et al. The relationship between proangiogenic gene expression levels in prostate cancer and their prognostic value for clinical outcomes. Prostate 2010 Nov 1, 70(15):1692-1700.
5. Wykoff CC, Beasley N, Watson PH, Campo L, Chia SK, English R, et al. Expression of the hypoxia-inducible and tumor-associated carbonic anhydrases in ductal carcinoma in situ of the breast. Am J Pathol 2001 Mar, 158(3):1011-1019.
6. Stewart RJ, Panigrahy D, Flynn E, Folkman J. Vascular endothelial growth factor expression and tumor angiogenesis are regulated by androgens in hormone responsive human prostate carcinoma: evidence for androgen dependent destabilization of vascular endothelial growth factor transcripts. J Urol 2001 Feb, 165(2):688-693.
7. Mukherjee P, Sotnikov AV, Mangian HJ, Zhou JR, Visek WJ, Clinton SK. Energy intake and prostate tumor growth, angiogenesis, and vascular endothelial growth factor expression. J Natl Cancer Inst 1999 Mar 17, 91(6):512-523.
8. Vergis R, Corbishley CM, Norman AR, Bartlett J, Jhavar S, Borre M, et al. Intrinsic markers of tumour hypoxia and angiogenesis in localised prostate cancer and outcome of radical treatment: a retrospective analysis of two randomised radiotherapy trials and one surgical cohort study. Lancet Oncol 2008 Apr, 9(4):342-351.
9. Zhong H, De Marzo AM, Laughner E, Lim M, Hilton DA, Zagzag D, et al. Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res 1999 Nov 15, 59(22):5830-5835.
10. Green MM, Hiley CT, Shanks JH, Bottomley IC, West CM, Cowan RA, et al. Expression of vascular endothelial growth factor (VEGF) in locally invasive prostate cancer is prognostic for radiotherapy outcome. Int J Radiat Oncol Biol Phys 2007 Jan 1, 67(1):84-90.
11. Schlomm T, Kirstein P, Iwers L, Daniel B, Steuber T, Walz J, et al. Clinical significance of epidermal growth factor receptor protein overexpression and gene copy number gains in prostate cancer. Clin Cancer Res 2007 Nov 15, 13(22 Pt 1):6579-6584.
12. Al-Ahmadie HA, Alden D, Qin LX, Olgac S, Fine SW, Gopalan A, et al. Carbonic anhydrase IX expression in clear cell renal cell carcinoma: an immunohistochemical study comparing 2 antibodies. Am J Surg Pathol 2008 Mar, 32(3):377-382.
13. Peraldo-Neia C, Migliardi G, Mello-Grand M, Montemurro F, Segir R, Pignochino Y, et al. Epidermal Growth Factor Receptor (EGFR) mutation analysis, gene expression profiling and EGFR protein expression in primary prostate cancer. BMC Cancer 2011, 11:31. 10.1186/1471-2407-11-31, 3040720, 21266046.
14. Blancher C, Moore JW, Talks KL, Houlbrook S, Harris AL. Relationship of hypoxia-inducible factor (HIF)-1alpha and HIF-2alpha expression to vascular endothelial growth factor induction and hypoxia survival in human breast cancer cell lines. Cancer Res 2000 Dec 15, 60(24):7106-7113.
15. Birner P, Schindl M, Obermair A, Plank C, Breitenecker G, Oberhuber G. Overexpression of hypoxia-inducible factor 1alpha is a marker for an unfavorable prognosis in early-stage invasive cervical cancer. Cancer Res 2000 Sep 1, 60(17):4693-4696.
16. Hutchison GJ, Valentine HR, Loncaster JA, Davidson SE, Hunter RD, Roberts SA, et al. Hypoxia-inducible factor 1alpha expression as an intrinsic marker of hypoxia: correlation with tumor oxygen, pimonidazole measurements, and outcome in locally advanced carcinoma of the cervix. Clin Cancer Res 2004 Dec 15, 10(24):8405-8412.
17. Beasley NJ, Leek R, Alam M, Turley H, Cox GJ, Gatter K, et al. Hypoxia-inducible factors HIF-1alpha and HIF-2alpha in head and neck cancer: relationship to tumor biology and treatment outcome in surgically resected patients. Cancer Res 2002 May 1, 62(9):2493-2497.
18. Fillies T, Werkmeister R, van Diest PJ, Brandt B, Joos U, Buerger H. HIF1-alpha overexpression indicates a good prognosis in early stage squamous cell carcinomas of the oral floor. BMC Cancer 2005, 5:84. 10.1186/1471-2407-5-84, 1190162, 16035955.
19. Shaida N, Chan P, Turley H, Jones CM, Kanga S, Ritchie RW, et al. Nuclear localization of factor inhibitor hypoxia-inducible factor in prostate cancer is associated with poor prognosis. J Urol 2011 Apr, 185(4):1513-1518.
20. Simon J, Comperat E, Beckendorf P, Bey P, Mazeron J, Jaillon P. Valeurs prédictives des expressions HIF-1 alpha et CAIX par les adenocarcinomes de la prostate traités par irradiation exclusive. Etude ancillaire du protocole GETUG 06. Cancer Radiother 2007, 11(Abstract P083):414.
21. Carmeliet P, Dor Y, Herbert JM, Fukumura D, Brusselmans K, Dewerchin M, et al. Role of HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature 1998 Jul 30, 394(6692):485-490.
22. Vaughan MM, Toth K, Chintala S, Rustum YM. Double immunohistochemical staining method for HIF-1alpha and its regulators PHD2 and PHD3 in formalin-fixed paraffin-embedded tissues. Appl Immunohistochem Mol Morphol 2010 Jul, 18(4):375-381.
23. Pipinikas CP, Carter ND, Corbishley CM, Fenske CD. HIF-1alpha mRNA gene expression levels in improved diagnosis of early stages of prostate cancer. Biomarkers 2008 Nov, 13(7):680-691.
24. Di Lorenzo G, Tortora G, D'Armiento FP, De Rosa G, Staibano S, Autorino R, et al. Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer. Clin Cancer Res 2002 Nov, 8(11):3438-3444.
25. Vuky J, Porter C, Isacson C, Vaughan M, Kozlowski P, Picozzi V, et al. Phase II trial of neoadjuvant docetaxel and gefitinib followed by radical prostatectomy in patients with high-risk, locally advanced prostate cancer. Cancer 2009 , 115(4):784-791. 10.1002/cncr.24092, 19130458.
26. Gyftopoulos K, Vourda K, Sakellaropoulos G, Perimenis P, Athanasopoulos A, Papadaki E. The angiogenic switch for vascular endothelial growth factor-A and cyclooxygenase-2 in prostate carcinoma: correlation with microvessel density, androgen receptor content and Gleason grade. Urol Int 2011, 87(4):464-469. 10.1159/000329289, 21912077.
27. Jackson MW, Bentel JM, Tilley WD. Vascular endothelial growth factor (VEGF) expression in prostate cancer and benign prostatic hyperplasia. J Urol 1997 Jun, 157(6):2323-2328.